Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases

被引:12
|
作者
Mostafa, Mahmoud [1 ]
Al Fatease, Adel [2 ]
Alany, Raid G. [3 ,4 ]
Abdelkader, Hamdy [2 ]
机构
[1] Minia Univ, Fac Pharm, Dept Pharmaceut, Al Minya 61519, Egypt
[2] King Khalid Univ, Coll Pharm, Dept Pharmaceut, Abha 62223, Saudi Arabia
[3] Kingston Univ London, Sch Pharm, Kingston Upon Tames KT1 2EE, England
[4] Univ Auckland, Sch Pharm, Auckland 1010, New Zealand
关键词
chronic eye diseases; inserts; implants; ocular delivery; IN-VITRO CHARACTERIZATION; VIVO PHARMACODYNAMIC EVALUATION; NANOSTRUCTURED LIPID CARRIERS; DRY-EYE; SUSTAINED-RELEASE; EX-VIVO; MACULAR DEGENERATION; OPHTHALMIC DELIVERY; HYALURONIC-ACID; AQUEOUS-HUMOR;
D O I
10.3390/pharmaceutics15061746
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic ocular diseases can seriously impact the eyes and could potentially result in blindness or serious vision loss. According to the most recent data from the WHO, there are more than 2 billion visually impaired people in the world. Therefore, it is pivotal to develop more sophisticated, long-acting drug delivery systems/devices to treat chronic eye conditions. This review covers several drug delivery nanocarriers that can control chronic eye disorders non-invasively. However, most of the developed nanocarriers are still in preclinical or clinical stages. Long-acting drug delivery systems, such as inserts and implants, constitute the majority of the clinically used methods for the treatment of chronic eye diseases due to their steady state release, persistent therapeutic activity, and ability to bypass most ocular barriers. However, implants are considered invasive drug delivery technologies, especially those that are nonbiodegradable. Furthermore, in vitro characterization approaches, although useful, are limited in mimicking or truly representing the in vivo environment. This review focuses on long-acting drug delivery systems (LADDS), particularly implantable drug delivery systems (IDDS), their formulation, methods of characterization, and clinical application for the treatment of eye diseases.
引用
收藏
页数:50
相关论文
共 50 条
  • [1] Recent Advances in Ocular Drug Delivery Systems
    Kuno, Noriyuki
    Fujii, Shinobu
    POLYMERS, 2011, 3 (01) : 193 - 221
  • [2] Recent advances in drug delivery systems for treating ocular complications of systemic diseases
    Lee, Susan S.
    Hughes, Patrick M.
    Robinson, Michael R.
    CURRENT OPINION IN OPHTHALMOLOGY, 2009, 20 (06) : 511 - 519
  • [3] Recent advances in ocular drug delivery
    Achouri, Djamila
    Alhanout, Kamel
    Piccerelle, Philippe
    Andrieu, Veronique
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2013, 39 (11) : 1599 - 1617
  • [4] Advances in ocular drug delivery systems
    Kang-Mieler, Jennifer J.
    Rudeen, Kayla M.
    Liu, Wenqiang
    Mieler, William F.
    EYE, 2020, 34 (08) : 1371 - 1379
  • [5] Advances in ocular drug delivery systems
    Jennifer J. Kang-Mieler
    Kayla M. Rudeen
    Wenqiang Liu
    William F. Mieler
    Eye, 2020, 34 : 1371 - 1379
  • [6] Advances in Ocular Drug Delivery Systems
    Silva-Cunha, Armando
    PHARMACEUTICS, 2021, 13 (09)
  • [7] Recent Advances in Topical Ocular Drug Delivery
    Yellepeddi, Venkata Kashyap
    Palakurthi, Srinath
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2016, 32 (02) : 67 - 82
  • [8] Recent advances in ocular drug delivery system
    Nagaich, Upendra
    JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH, 2014, 5 (04) : 151 - 151
  • [9] Recent advances of smart materials for ocular drug delivery
    Wang, Xiaojun
    Luan, Fuxiao
    Yue, Hua
    Song, Cui
    Wang, Shuang
    Feng, Jing
    Zhang, Xiao
    Yang, Wei
    Li, Yuxin
    Wei, Wei
    Tao, Yong
    ADVANCED DRUG DELIVERY REVIEWS, 2023, 200
  • [10] Advances in Nanogels for Topical Drug Delivery in Ocular Diseases
    Wu, Yongkang
    Tao, Qing
    Xie, Jing
    Lu, Lili
    Xie, Xiuli
    Zhang, Yang
    Jin, Yong
    GELS, 2023, 9 (04)